Quiz 1 Flashcards
- Affect who more? 4
- m/c disability in US?
- 66% of those diagnosed with arthritis are?
- More common over age of?
- Affects women more than men
- Leading cause of disability among persons age 65 and older in the US
- 66% of those diagnosed with arthritis are overweight or obese
- More common over age 65 (49.5%)
The most famous transmembrane PRRs are called?
toll-like receptors (TLRs) – they play a huge roll in autoimmune diseases
Common molecules that trigger innate immunity: 2
- Pathogen-associated molecular patterns (PAMPs) – microbial molecules “Intestinal dysbiosis” (turn it on or off)
- Damage-associated molecular patterns (DAMPs) – molecules from damaged or necrotic host cells (Cell destruction)
•Activated complement does the following: 3
- Coats microbes
- Stimulates phagocytosis
- Chemotaxis of leukocytes
- Stimulates inflammation
- Cause direct cell lysis
- Coats microbes and stimulates phagocytosis by the innate immune system
- Promotes chemotaxis of leukocytes and stimulates inflammation
- Forms a complex that can cause direct cell lysis
•C3 and C4 can be measured in the blood: 2
- Increased values: cancer, infection, UC
* Decreased values: liver disease, autoimmune disease (lupus), kidney disease.
B Cell Lymphocytes do what?: 2
- Present
- Recognise antigens
- B-cells present antigens to T-helper cells through MHC peptides
- Antibodies are responsible for recognizing antigens – they can stimulate the complement cascade, activate phagocytes or stimulate activation of T-cells.
T cell Lymphocytes do what?: 3
- stimulate further immune response
- (MHC) bind to T-cells (at TCRs) and stimulate activation.
- MHC in humans = known as (HLAs) - human leukocyte antigens -> highly polymorphic
- Their biggest function is to interact with other cells to stimulate further immune response (phagocytes/B cells) or kill infected cells.
- Major histocompatibility complexes (MHC) on antigen presenting cells will bind to T-cells (at TCRs) most often and stimulate activation.
- MHC proteins in humans are known as human leukocyte antigens (HLAs) – they are highly polymorphic in humans.
Types of T-Cells: 3 (MEN)
- Th1 – produce IFN-gamma – associated with macrophages, autoimmunity and chronic inflammation
- Th2 – produce IL-4, IL-5, IL-13 – associated with eosinophils and allergy
- Th17 – produce IL-17, IL-22 – associated with neutrophils and autoimmunity
MEN- macrophages Th1, eosinophils Th2, neutrophils Th3
Immunogenic Determinants: 7
- Foreignness (“self” vs “non-self”)
- Molecular size (The bigger the protein, the more immunogenic it tends to be)
- Chemical-structural complexity
- Antigenic determinants (epitopes) (Different epitopes can elicit different immune responses)
- Dosage, route and timing of antigen administration
- Genetic constitution of the host (HLA genes)
- Adjuvants – or immune system enhancers
The Development of Autoimmunity: 4 (SIP-R)
•Onset of autoimmune response and development of clinical symptoms are generally separated in time.
- Susceptibility phase
- Initiation phase
- Propagation phase
- Regulation/resolution phase
- Susceptibility phase – several preconditions for disease are satisfied (Environment)
- Initiation phase – autoimmune response present but no clinical disease
- Propagation phase – clinical disease begins
- Regulation/resolution phase – immunoregulatory pathways activated; may result in resolution but this is rare.
Autoimmunity Pathogenesis: 2
Environmental triggers for autoimmunity: 6
- Susceptible genes + environmental triggers are needed to trigger autoimmunity.
- Many autoimmune diseases are linked to HLA (MHC) alleles.
•Environmental triggers for autoimmunity:
- Hormone production (Reproductive & Cortisol)
- Infections
- Microbial flora (skin, GI, vaginal…etc)
- UV radiation
- Toxic exposure (heavy metals, pharmaceuticals…etc)
- Diet and lifestyle (obesity, food allergies…etc)
Laboratory Assessment:
*Common Basic Laboratory Testing: 8
- CBC
- Chem Panel
- CRP/ESR
- Serum Ferritin
- Thyroid Panel
- 25-Hydroxy Vitamin D
- Specific antibody testing
- Serum uric acid
Pharmacologic Treatment:
•NSAIDs- CV event-just helps w/pain
Action & MOA- 3
- Actions: analgesic, anti-inflammatory, antipyretic
- MOA: inhibit cyclooxygenase (COX) activity
- NSAIDs DO NOT stop progression of tissue injury
Pharmacologic Treatment:
NSAIDs Adverse effects: 3
- Increased risk of MI, stroke and death
- Gastrointestinal bleeding, hemorrhage and perforation
- Acute renal failure
Pharmacologic Treatment:
•Glucocorticoids-Tapered/topical injections to jts- 4
- Used to modify disease progression in acute flares
- Actions: reduce activation, proliferation and differentiation of immune cells
- Glucocorticoids are often not used in OA, Scleroderma and Sjögren’s
- Glucocorticoids HAVE to be tapered down